ICIs, antibodies that target the cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) and programmed cell death protein 1 (antiPD-1), are used to treat unresectable melanoma, resulting in a dramatic improvement in survival of patients [28]. Here, CTLA4 is linked to melanoma.